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Abstract Despite important advances in the treatment of
multiple sclerosis (MS) over recent years, the introduction
of several disease-modifying therapies (DMTs), the burden
of progressive disability and premature mortality associ-
ated with the condition remains substantial. This burden,
together with the high healthcare and societal costs asso-
ciated with MS, creates a compelling case for early treat-
ment optimization with highly efficacious therapies. Often,
patients receive several first-line therapies, while more
recent and in part more effective treatments are still being
introduced only after these have failed. However, with the
availability of highly efficacious therapies, a novel treat-
ment strategy has emerged, where the aim is to achieve no
evidence of disease activity (NEDA). Achieving NEDA
necessitates regular monitoring of relapses, disability and
functionality. However, there is only a poor correlation
between conventional magnetic resonance imaging mea-
sures like T2 hyperintense lesion burden and the level of
clinical disability. Hence, MRI-based measures of brain
atrophy have emerged in recent years potentially reflecting
the magnitude of MS-related neuroaxonal damage. Cur-
rently available DMTs differ markedly in their effects on
brain atrophy: some, such as fingolimod, have been shown
to significantly slow brain volume loss, compared to pla-
cebo, whereas others have shown either no, inconsistent, or
delayed effects. In addition to regular monitoring, treat-
ment optimization also requires early intervention with
efficacious therapies, because accumulating evidence
shows that effective intervention during a limited period
early in the course of MS is critical for maintaining neu-
rological function and preventing subsequent disability.
Together, the advent of new MS therapies and evolving
management strategies offer exciting new opportunities to
optimize treatment outcomes.
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Introduction
Although recent years have seen great advances in the
treatment of multiple sclerosis (MS), with an increasing
number of disease-modifying therapies (DMTs) becoming
available, it remains a potentially serious and debilitating
condition as none of the current treatments halts or cures
the disease. A broad range of neurological functions may
be affected, including vision, gait and motor function,
cognition, coordination, and balance, as well as bladder,
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bowel and sexual function [1]. Cognitive impairment, for
example, is present in up to 82 % of patients with MS [2–
5]: it can be detected in the earliest stages of the disease
[5], and adversely affects employment, activities of daily
living, and social function [3, 6, 7]. Furthermore, in most
cases, MS causes progressive disability, which can involve
both motor and cognitive function and has a detrimental
impact on patients’ quality of life [8]. Indeed, there is
evidence that the impact of MS-related fatigue, unem-
ployment and limited mobility on quality of life is greater
than that associated with other causes of disability [9, 10].
MS-related disability is a major driver of the substantial
healthcare and social costs associated with the condition
[7]: European [11] and US [9, 12] data suggest that
approximately 40–44 % of total MS-related costs result
from lost productivity.
In addition to the physical and cognitive impairment
associated with MS, life expectancy in people with MS is
on average 8–12 years shorter than in the general popula-
tion [13–16]. Up to approximately 78 % of people with MS
die of disease-related complications such as respiratory
tract infections or accidents [16–19]. This burden of dis-
ability and premature mortality, and the substantial eco-
nomic costs associated with the condition, create a
compelling case for early intervention and early treatment
optimization with the more efficacious treatments that are
now becoming available. At present, it is common practice
in many countries for patients to receive several first-line
therapies, such as interferon (IFN)-b, glatiramer acetate,
teriflunomide or dimethyl fumarate (DMF), before thera-
pies with greater efficacy, such as fingolimod, natalizumab
or alemtuzumab, are tried following failure of these first-
line agents [20]. However, there is increasing evidence that
both early intervention after diagnosis, and early treatment
optimization in the event of insufficient response to initial
treatment (Fig. 1), are critical to achieving a favourable
outcome and reducing the progressive burden imposed by
MS on the patients, their families, and society as a whole
[21].
The question of how best to intervene early in MS in
order to achieve an optimal outcome was discussed at a
round-table meeting in Barcelona, Spain, in June 2013. The
key outcomes from this meeting are summarized in this
paper.
Monitoring disease activity in multiple sclerosis
Monitoring MS disease activity is key to achieving opti-
mal outcomes. However, the heterogeneity of the disease,
and the complexity of the underlying biological mecha-
nisms, can render this challenging. MS pathology is
characterized by two major hallmarks: inflammation and
progressive neuroaxonal damage [23–27]. From a clinical
perspective, inflammation is infrequently associated with
the subacute onset of clinical signs and symptoms and
focal lesions on magnetic resonance imaging (MRI) that
usually show temporary permeability of the blood–brain
barrier, reflected by contrast enhancement at sites of acute
inflammation. By contrast, axonal degeneration and loss of
neurons are associated with sustained disability and evi-
dence of brain or spinal cord atrophy on MRI over time
(Fig. 2) [28]. Axonal transection is a consistent patholog-
ical feature of acute MS lesions, and the incidence of
neuronal damage correlates with the extent of inflamma-
tion within the lesion [25]. Importantly, such damage may
be present in the early stages of MS [27]. It can, however,
be masked by mechanisms such as recruitment of other
neuronal pathways or cortical remodelling, that compen-
sate for functional loss; hence, progressive damage may go
unrecognized until it is too late for an intervention to be
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Fig. 1 The ‘windows of opportunity’ for treatment optimization in
MS. Early initiation of treatment, and prompt intervention if disease
activity persists despite initial treatment, are both critical to optimiz-
ing treatment outcomes. In both cases, there is only a limited period
during which intervention will be effective. Adapted with permission
from Tintore´ [22]
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Fig. 2 Associations between inflammatory and degenerative pro-
cesses in MS and the clinical and MRI features of the disease
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beneficial [29, 30]. As the disease progresses, the balance
between degenerative and reparative processes shifts,
resulting in progressive neuroaxonal degeneration and
increasing disability (Fig. 3). Hence, clinical disease
monitoring in MS should have three elements: disease
activity as manifested in relapses (reflecting inflamma-
tion), disability (reflecting neuroaxonal loss) and func-
tionality (reflecting the degree of compensation or cerebral
reserve) (Fig. 4).
Monitoring MS by clinical parameters: relapses
versus disability
In the majority of MS patients, the disease initially takes a
relapsing–remitting course (RRMS), characterized by acute
symptomatic relapses followed by periods of variable
recovery. In the absence of treatment, more than 50 % of
patients with RRMS will develop progressive disability
after approximately 15 years [31].
Natural history studies have provided important insights
into the determinants of disability progression in early MS.
One such study showed a significant association between
relapses occurring in the early stages of MS and long-term
disability, which was primarily driven by an increasing risk
of SPMS and, to a lesser extent, by an effect of frequent
relapses on the rate of progression [32]. A further study [33]
found that age at onset of MS, residual deficits after a first
relapse, and the number of relapses during the first 2 years
were predictive of the time to a Disability Status Score (DSS)
of 3 (moderate disability), but not of the time from DSS 3 to
DSS 6 (requiring assistance to walk). The authors suggested
that these findings would be consistent with a two-phase
process of progressive disability, in which the first stage is
related to focal inflammation that is amenable to treatment,
whereas the second stage is independent of current inflam-
mation and may be related to diffuse neurodegeneration [33].
Monitoring MS by MRI: inflammatory activity
versus destructive markers
Conventional MRI techniques, such as T2-weighted
imaging and gadolinium (Gd)-enhanced T1-weighted
imaging (Table 1) offer good sensitivity in assessing the
location and temporal evolution of demyelinating plaques
in the brain and spinal cord of MS patients; indeed, these
techniques are considered to represent the ‘gold standard’
for diagnosing MS and monitoring the response to treat-
ment [31, 34]. However, due to the limited pathological
specificity of these techniques, they provide little infor-
mation about the underlying inflammatory process in MS,
and show only weak correlations with clinical measures of
disability [31, 34].
Alternatively, this apparent lack of correlation between
conventional MRI measures and clinical disability could
also be due to the low sensitivity of clinical measures of
disability applied in routine clinical practice. For example,
the widely used Expanded Disability Status Scale (EDSS)
reflects the level of damage that has already occurred, and
Functional brain activation
“Brain reserve”
with compensation
Disease duration
Disability
Relapses
Inflammatory
lesions
Brain 
volume
loss
Fig. 3 The relationship between relapses, inflammation and disabil-
ity in MS. The disease process in MS is characterized by both
inflammation and progressive neuroaxonal damage. Importantly, such
damage may be present in the early stages of MS, but may be masked
by compensatory mechanisms; hence, progressive damage may go
unrecognized until it is too late for intervention to be beneficial. As
the disease progresses, the balance between degenerative and
reparative processes shifts, resulting in progressive neuroaxonal
degeneration and increasing disability
Fig. 4 Potential treatment strategies in MS. In patients with little
evidence of disease activity at baseline, treatment can be started with
conventional first-line therapies such as IFN-b, glatiramer acetate,
DMF or teriflunomide. Treatment should be monitored every 6–12-
months. For patients with highly active disease at baseline or rapidly
evolving severe disease (C2 disabling relapses in 1 year, with at least
one Gd? lesion on T1-weighted MRI or a significant increase in
lesion load on T2-weighted MRI), newer agents can be used as first-
line therapy. The main differences between these two strategies are
the higher responder rate and the earlier onset of action with the latter,
which has to be evaluated for each individual patient
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provides no information about the underlying neurode-
generative and reparative processes. Other MRI techniques,
such as magnetization transfer (MTR), diffusion-tensor
imaging (DTI) and proton magnetic resonance spec-
troscopy (MRS) (Table 1), appear to provide better and
more quantitative measures of higher pathological speci-
ficity for hallmarks of the disease such as demyelination
and remyelination (MTR, DTI) or axonal degeneration
(MRS, DTI). Moreover, they show better correlations with
standard measures of clinical disability [31, 34].
In addition to focal MRI lesions, MRI measurements of
more diffuse brain atrophy have emerged in recent years as a
promising measure of MS-related neuroaxonal damage, that
could in principle be used to measure treatment effects [35–
37]. Brain atrophy is a characteristic feature of MS, occur-
ring in the earliest stages and progressing throughout the
course of the disease [38]. In people with MS, brain atrophy
progresses at a rate of approximately 0.5–1.0 % per year,
compared with 0.2–0.4 % in healthy individuals [35, 39],
although it should be noted that it is unclear whether atrophy
progresses in a linear fashion in individual patients. Of note,
changes in brain volume in MS can reflect diverse patho-
physiological mechanisms, including changes in inflamma-
tory oedema, neuronal or axonal loss, de- and remyelination,
and changes in glial cell number and volume [35, 39].
Several studies have shown that, at a group level, brain
atrophy in MS patients appears to be predictive of subse-
quent disability [40, 41]. Indeed, it has been suggested that
measurement of brain atrophy may be the best predictor of
subsequent disability in MS patients [37, 42, 43]. Although
atrophy affects both grey and white matter regions of the
brain [37, 42], there is evidence that grey matter (cortical
and deep grey matter) atrophy is more closely related to
long-term disability than white matter atrophy. In one
study, for example, grey matter atrophy showed significant
correlations with disability measured either by the EDSS or
the MS functional composite (MSFC), whereas no such
correlations were seen with white matter atrophy; further-
more, changes in the grey matter fraction accounted for a
greater proportion of the variability in clinical findings than
changes in white matter [44]. Importantly, a recent patho-
logical study has shown that plaque-like primary
demyelinating cortical lesions are specific to MS, and are
not seen in other neuroinflammatory disorders such as
tuberculous meningitis or chronic purulent meningitis [45].
Recent studies have shown that the combination of brain
atrophy measures and MRI lesion load is a strong predictor
of long-term disability. In a study of 261 MS patients in
whom EDSS assessments were available at baseline and
after 10 years’ follow-up, and in whom MRI investigations
Table 1 Conventional and
emerging techniques used in the
assessment of MS [34]
Technique Role in MS
Gd-enhanced T1-weighted imaging Identification of demyelinated lesions (hypointense 
loci)
T2-weighted imaging Identification of demyelinated lesions (hyperintense 
loci)
2- and 3-dimensional fluid-attenuated 
inversion recovery (FLAIR) 
sequences
Identification of cortical, periventricular and 
infratentorial lesions
Double inversion recovery sequences
Ultra-high field strength MRI Detection of subpial cortical and deep grey matter 
lesions
Unenhanced T1-weighted imaging Detection of hypointense black holes, a measure of 
chronic neurodegeneration
Magnetization transfer imaging 
(MTI)
Characterization of the evolution of MS lesions and 
normal-appearing brain tissue
Diffusion-weighted imaging Provides information on orientation, size and 
geometry of white and grey matter damage
Magnetic resonance spectroscopy Provides information on tissue biochemistry, 
metabolism and function; detection of 
neuroprotective processes
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were performed over 1–2 years after baseline, the combi-
nation of these MRI measures was strongly predictive of
EDSS scores after 10 years (R2 = 0.74); furthermore,
central atrophy was predictive of long-term disability in
patients with minimal impairment (EDSS 0–3.5) at base-
line, whereas T2 lesion volume was predictive in patients
with moderate impairment (EDSS 4–6) at baseline [46].
A recent meta-analysis, including data from more than
13,500 patients enrolled in 13 randomized controlled trials,
has investigated the relationship between changes in brain
atrophy and disease progression during treatment of RRMS
[47]. Treatment effects on both brain atrophy and active
MRI lesions (defined as new or enlarging T2 lesions) were
significantly and independently correlated with effects on
disability progression at group level, and the correlation
was strongest when both MRI endpoints were included in a
multivariate model.
The available DMTs appear to differ in their effects on
brain atrophy (Table 2) [36, 50–70], although it should be
noted that direct comparisons are difficult between trials
because of the heterogeneity of patient populations and
methods applied to measure brain volume used in dif-
ferent studies. During treatment with many DMTs, an
apparent decrease in brain volume (pseudoatrophy) occurs
during the first 6–9 months, but a significant decrease in
atrophy rate, compared with placebo, occurs during the
second year of treatment with some agents [56, 61, 63,
71–77].
At present, brain atrophy is not measured routinely in
MS centres and is not used to monitor treatment. Hence,
the use of brain atrophy as an outcome measure in MS will
require standardization of MRI acquisition and post-pro-
cessing procedures to allow comparisons of scans obtained
at different times during the course of MS and at different
centres. In clinical trials, brain volume should be measured
at 3–6 month intervals to identify pseudoatrophy [78, 79],
while in routine clinical practice scans should be taken
6 months after starting DMTs to establish a baseline for
assessments of brain atrophy that is less likely confounded
by pseudoatrophy effects. SIENA (Structural Image Eval-
uation, using Normalization, of Atrophy), usually used to
measure brain volume loss in clinical trials, could
Table 2 Immediate and delayed treatment effects on brain volume changes in the double-blind phases of trials of disease-modifying therapies in
RRMS [48–70]
Drug Numbers of patients Global effect on brain
volume
Immediate effect on brain
volume
Delayed effect on brain
volume
Placebo-controlled studies
Interferon b-1a [48–51] 172, 382 No No Yes
Glatiramer acetate [52–55] 27 (subcohort), 207,
980
No Noa NAb
Fingolimod [56–58] 1033, 1153 Yes Yes Yes
Dimethyl fumarate [59, 60] 540, 681 Yesc Nod Yesd
Teriflunamide [63] 1074 No No No
Laquinimod [64, 65] 1106, 1331 Yes NA NA
Natalizumab [61, 62] 942, 1003 No No Yes
Active comparator studies
Interferon versus glatiramer acetate
[66–68]
460, 1008, 2096 Yes (GA)e Yes (GA)e Yes (GA)e
Fingolimod versus im IFN b-1a
[57]
1153 Yes (FTY) Yes (FTY) NAf
Alemtuzumab versus sc IFN b-1a
[69, 70]
334, 581, 840 Yes (AL) NAg NAg
Adapted from Vidal-Jordana et al. [48]
AL alemtuzumab, IFN interferon, im intramuscular, GA glatiramer acetate, NA not applicable, sc subcutaneous
a Baseline to 9 months
b Open-label data: a significant effect of glatiramer acetate was observed in months 9–18 in the early treatment arm
c Only for twice-daily dosing in the DEFINE trial; brain volume was assessed during the 6–24 month period
d Only for twice-daily dosing in the CONFIRM trial: no data available for the DEFINE trial
e Data only from the REGARD trial, no P values reported; no significant differences were observed in the BEYOND AND COMBIRx trials
f No data available beyond 12 months
g The two CARE-MS trials only assessed brain volume changes from baseline to 24 months
J Neurol (2016) 263:1053–1065 1057
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potentially be incorporated into MS management but
would still necessitate a technology and staff infrastructure
not necessarily available in MS centers. However, other
simpler techniques such as measurement of third ventric-
ular width, lateral ventricle volume and corpus callosum
index might provide alternative options once validated in
clinical routine [37, 42, 80, 81].
Monitoring MS by patient-reported outcomes
From a patient’s perspective, a treatment may be consid-
ered to be a failure if it produces adverse events that affect
everyday quality of life. This would suggest that worsening
in patient-reported outcomes related to fatigue, depression,
cognitive dysfunction, mobility, sexual function or bowel/
bladder function should also be included in definitions of
treatment failure [1]. Similarly, in view of the significant
impact of MS-related disability on quality of life [8],
changes in quality of life should be considered an impor-
tant outcome in MS treatment (Fig. 4).
It may be anticipated that patient-reported outcomes will
become increasingly important in MS management as the
focus of treatment moves to the prevention or delay of
disability, rather than clinical relapses or MRI measures of
disease activity [82]. It will therefore be necessary to val-
idate such outcome measures in clinical trials and routine
practice [83]. A recent study has found that two widely
used outcome measures, the MS Impact Scale (MSIS-29)
and the Hamburg Quality of Life Questionnaire in MS
(HAQUAMS), are able to differentiate between MS
patients with different degrees of functional impairment,
with moderate correlations between these instruments and
conventional disability measures such as the EDSS and the
MSFC [84].
Combining monitoring strategies in MS treatment:
the NEDA concept
As noted above, current practice in MS is to start with first-
line therapies and then introduce more efficacious agents if
the response is inadequate or if first-line therapy is poorly
tolerated [19]. This approach is enshrined in current MS
management guidelines from a number of European
countries [85, 86]. In recent years, however, a new strategy
has emerged, ‘treating to target,’ where the aim is to
achieve no evidence of disease activity (NEDA). This may
be defined as absence of relapses, disability progression
and MRI measures of disease activity including new
Gadolinium enhancing and new or newly enlarging T2
lesions [87]. There is evidence that MS patients treated to
target of NEDA have better outcomes than those with
clinical or subclinical breakthrough disease, and hence it
has been recommended by some that this approach should
be incorporated into routine clinical practice [88]. A recent
long-term (up to 7 years) study found that NEDA status at
2 years had optimal prognostic value, although NEDA was
difficult to sustain over the longer term, even with treat-
ment [89]. In this study, NEDA was defined as a composite
of absence of relapses, no EDSS progression and no new or
enlarging T2 or T1 Gd-enhancing lesions on annual MRI.
However, it has been argued that such a focus on clinical
and MRI measures does not adequately reflect patients’
needs in routine clinical practice [90].
In view of such considerations, it is anticipated that the
definition of NEDA is likely to evolve as evidence accu-
mulates to support the incorporation of additional outcome
measures [88]. For example, there is increasing evidence
that the absence of brain atrophy, as measured by MRI,
may also be a valid criterion for NEDA. This view is based
on the evidence, discussed above, that measures of brain
atrophy, despite methodological limitations, appear to be a
clinically useful marker of neuroaxonal damage in MS;
indeed, early brain atrophy has recently been shown to be
predictive of response to IFN-b treatment [91]. The com-
bination of relapses, disability progression and conven-
tional MRI measures with assessment of brain volume loss
has been termed NEDA-4 [92]. In an analysis of two piv-
otal trials with fingolimod, the addition of brain volume
loss increased the stringency of the NEDA measure without
affecting the sensitivity of the measurement to treatment
effects [92]. However, regular MRI monitoring of brain
volume may not be currently feasible in routine clinical
practice due to limited availability of the technological
infrastructure and trained staff as indicated above.
The increasing focus on NEDA as an aim of MS therapy
implies that regular, systematic, monitoring should be a
central aspect of the management of the condition, and this
is reflected in recent Canadian guidelines that recommend
the implementation of MRI monitoring, ultimately advo-
cating implementation of NEDA-4 as an aspirational goal
[93]. These guidelines recommend regular MRI follow-up,
beginning at 3–6 months after initiation of treatment, at
6–12 months after the reference scan and annually there-
after [93].
The importance of early diagnosis and early
treatment in MS
Evidence is accumulating to support the assumption that
there is a period early in the course of MS during which
treatment is most efficacious, and that effective treatment
during this period appears to be critical for maintaining
long-term neurological function and preventing subsequent
disability and premature mortality over the lifetime of the
patient.
1058 J Neurol (2016) 263:1053–1065
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Several clinical trials have provided proof of concept for
an early window of first treatment intervention in clinically
isolated syndrome (CIS). Results from the 2-year blinded
phase of the BENEFIT study [94] in patients with a first
event suggestive of MS showed that the time to confirmed
progression on the EDSS was significantly longer in those
receiving early treatment than in those who were on pla-
cebo, and so had a delayed start of treatment, and the risk
of progression was reduced by 40 % [hazard ratio (HR)
0.60, 95 % confidence interval (CI) 0.39–0.92, P = 0.022].
The authors noted that, although the delay in treatment was
equivalent to just a single clinical event, this was never-
theless sufficient to influence the subsequent accumulation
of disability, and that the delay in progression associated
with early treatment could be considered to be clinically
relevant [94]. A subsequent analysis after 5 years of fol-
low-up showed that the rate of progression to clinically
definite MS was significantly lower with early treatment
than with delayed treatment, although the risk of confirmed
progression of disability did not differ between the groups
and mean EDSS scores were low [73]. Other IFN-b studies
[95–99] showed that, compared with placebo, early inter-
vention significantly reduced the risk of progression to
clinically definite MS in patients with a first clinical event
suggestive of MS, and similar results have been obtained
with glatiramer acetate [100] and teriflunomide [101].
Further evidence for a critical period for early inter-
vention in MS comes from a study with alemtuzumab,
which involved both an SPMS and an RRMS cohort [102].
The mean (±SD) disease duration at the start of alem-
tuzumab treatment was 11.2 ± 6.1 years in the secondary
progression cohort, of which an average of 3.6 ± 2.6 years
had been spent in the progressive phase, whereas in the
RRMS group the mean duration of disease prior to treat-
ment was 2.7 ± 2.9 years. In the RRMS cohort, treatment
with alemtuzumab significantly reduced relapse rates,
prevented the accumulation of disability, and allowed some
patients to recover function as measured by the EDSS; by
contrast, in patients with SPMS alemtuzumab suppressed
inflammation and slowed (but did not prevent) progressive
disability, and there was little recovery of function. These
findings were attributed by the authors to the beneficial
effects of early rescue of neurons from an inflammatory
environment [102]. Additional evidence comes from the
results of an extension phase to the FREEDOMS study, in
which patients who received placebo during the double-
blind phase were switched to fingolimod. Although these
patients showed significant clinical improvements, includ-
ing reductions in relapse rates, disability progression and
brain atrophy, following initiation of fingolimod, these
benefits were less marked than in patients who received
fingolimod treatment from the start of the study [103].
Early treatment optimization
MRI lesions and clinical endpoints
A recent 15-year follow-up study of RRMS patients who
received IFN-b-1a during a pivotal clinical trial has shown
that the presence of at least two Gd-enhancing lesions over
the 2-years of treatment in the IFN arm of the study was
strongly predictive of EDSS worsening [104]. In a further
study, the presence of two or three measures of disease
activity (new MRI lesions, relapses or confirmed 1-point
EDSS progression) during the first year of IFN-b treatment
was predictive of a subsequent poor response to therapy
[105].
A scoring system for MS disease activity was described
by Rı´o et al. [106], who analysed data from 222 patients
with RRMS who had received IFN-b1a for at least 1 year.
This system was based on measurements of clinical
relapses, disability progression (increase of 1 EDSS point
confirmed at 6 months) and active MRI lesions (C2 new
T2 or Gd-enhancing lesions) 1 year after the start of
treatment. Patients who met at least two of these criteria
were more likely to experience progressive disability or
relapses during the subsequent 2 years than those who did
not. However, relapses or MRI criteria alone were not
predictive of new disease activity or disease progression.
By contrast, Prosperini et al. [107] found that the 4-year
outcomes of patients with isolated MRI activity after the
first year of IFN-b therapy did not differ from those ful-
filling the European Medicines Agency (EMA) criteria for
second-line treatment escalation. This would suggest that
MRI alone might be a good predictor of outcome.
A modified version of the Rı´o scoring system has
recently been published, based on relapses and focal MRI
activity only [108, 109]. Validation of this system in the
dataset used to develop the original Rı´o system resulted in
a 24 % probability of disease progression in patients con-
sidered to be at low risk of progression, a 33 % probability
in medium-risk patients, and a 65 % probability in high-
risk patients; a subsequent study showed that more efficient
classification of medium-risk patients could be achieved by
further MRI and clinical evaluation 6 months after the first
year of therapy [110].
In a long-term (16 years) retrospective follow-up of a
pivotal IFN-b trial, baseline EDSS scores correlated with
both physical and cognitive outcome (R2 = 0.22 and 0.12,
respectively, P\ 0.0001 for both), while accumulation of
disability during the course of the study correlated signif-
icantly with physical outcome (R2 = 0.11, P\ 0.0001),
but not with cognition [111]. By contrast, baseline MRI
measures of atrophy and lesion burden correlated with
cognitive outcome (R2 = 0.21, P\ 0.0001), but not with
J Neurol (2016) 263:1053–1065 1059
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physical outcome. These findings offer support for the
hypothesis that long-term outcome in MS is influenced at
least in part by disease activity during the initial years of
the disease.
The growing evidence, discussed above, that there is
only a limited window of opportunity for effective inter-
vention in MS with currently available drugs would suggest
that regular monitoring during treatment with DMTs, and
prompt intervention in cases of suboptimal response or
treatment failure, are essential to prevent long-term dis-
ability. (Although it should be noted that the impact of
early treatment switching has, to date, been studied only in
patients receiving IFN-b.) As described previously, at
present it is common for a patient to receive several first-
line therapies, with escalating doses or treatment switches
if the responses are inadequate, before more efficacious
therapies are tried [20]. The available evidence suggests
that switching to a different class of DMT (either as
another first-line therapy or as second-line treatment) is
more effective than dose escalation or switching to another
member of the same class [83, 84, 112–117]. For example,
in the CARE-MS II study, treatment with alemtuzumab
reduced relapse rates and disability in RRMS patients who
had previously experienced at least one relapse during first-
line treatment with IFN b-1a or glatiramer acetate [117].
However, there is also evidence that initiating treatment
with newer agents may be more effective than introducing
these agents as second-line treatment. For example, in a
randomized extension to the TRANSFORMS study,
patients who received fingolimod from the start of the trial
showed better clinical and MRI outcomes than those
originally randomized to IFN-b-1a and subsequently
switched to fingolimod during the extension phase [118].
Currently, highly effective DMTs such as fingolimod,
natalizumab and alemtuzumab are mainly licensed for the
first-line treatment of patients with highly active MS; fur-
ther clinical data, including cost-effectiveness data, will be
needed to support the early use of such therapies [119].
Based on the evidence currently available, a number of
potential strategies for the management of MS can be
defined, depending on the level of disease activity (Fig. 5).
In patients with little evidence of disease activity at base-
line, treatment can be started with conventional first-line
therapies such as IFN-b, glatiramer acetate, DMF or teri-
flunomide. Treatment should be monitored at 6–12-month
intervals, and highly effective agents such as fingolimod,
natalizumab, or alemtuzumab substituted (subject to their
licensing conditions) if signs of disease activity such as
frequent relapses, increasing disability, or worsening MRI
lesion burden (and possibly brain atrophy) are observed.
For patients with highly active disease at baseline or
rapidly evolving severe disease (C2 disabling relapses in
1 year, with at least one Gd? lesion on T1-weighted MRI
or a significant increase in lesion load on T2-weighted
MRI), newer agents can be used as first-line therapy, and
treatment monitored to ensure that NEDA is achieved.
ability to work
mobility partnership,
sexuality
cognition
pain
bladder & 
bowel
functionvision & 
speech
Fatigue
Standardized semiquantitative MRI benchmarking PRO
Fig. 5 Assessment of patients at risk of disease progression or
treatment failure will require attention to both traditional outcome
measures, such as relapses and disability, and to newer measures such
as MRI assessments of brain atrophy and patient-reported outcomes
(PROs). This in turn will require benchmarking to establish baseline
levels of disability, allowing longitudinal assessments of disability
over time, and standardized MRI protocols to monitor treatment
effects on brain atrophy
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While these strategies focus on clinical and MRI measures
of disease activity, it should be noted that patient-reported
progression of symptoms, adverse effects of treatment, and
an inability to tolerate injections may also constitute
grounds for switching treatments. There are currently no
data to suggest that the early use of effective treatments
presents a risk of ‘therapeutic burn-out.’ Rather, the clear
evidence for a limited therapeutic window militates in
favour of early intervention and treatment optimization.
The increasing number of highly active treatments
becoming available raises the possibility of sequential
treatment where necessary.
Conclusions
The introduction of highly effective treatments, such as
fingolimod, natalizumab and alemtuzumab, has consider-
ably expanded treatment options in MS. At the same time,
the choice of treatment has assumed a new importance for a
number of reasons. In particular, there is strong evidence
that there is a limited time window to intervene effectively
in patients with early MS, and that intervention during this
period appears to be critical for achieving favourable long-
term outcomes. Furthermore, a new therapeutic strategy,
treating to target to achieve no evidence of disease activity,
has emerged, and this may entail preservation of brain
tissue in addition to the traditional endpoints of clinical
relapses and MRI measures of inflammation. Importantly,
treating to target necessitates regular monitoring of disease
activity to allow prompt switches in cases of treatment
failure.
Effective intervention during the window of opportunity
requires identification of, and prompt response to, subop-
timal response or treatment failure. However, it is difficult
to define treatment failure adequately because much dis-
ease activity in MS (particularly during the early stages) is
subclinical, and hence it is not usually possible to be sure
that no disease activity is present and long-term conse-
quences are—at least in part—unknown. It is therefore
necessary to look for the best outcomes in groups of
patients included in clinical trials in order to identify the
most effective therapies. As emphasized above, it will also
be necessary to monitor treatment with DMTs systemati-
cally and consistently in order to identify suboptimal
response or treatment failure promptly. This will necessi-
tate attention both to traditional clinical endpoints such as
relapses and disability (with benchmarking of baseline
levels of disability), and to newer outcome measures such
as brain atrophy (measured using standardized MRI pro-
tocols, cognition and patient-reported outcomes (Fig. 5).
The regular assessment of the patient can be supported by a
computerized patient management system including PRO
assessment, such as the MSDS 3D system [120], partici-
pation in registries which provide bench marking function,
and standardized semi-quantitative MRI.
The evolving MS landscape, in which a number of new
treatments are appearing—each with their own benefits and
risks—will require a change in the nature of interactions
between patients and their physicians, with a shared
approach to clinical decision making that emphasizes
patient-related goals. Together, these innovations in MS
management offer exciting new opportunities to optimize
treatment outcomes.
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